
|Videos|April 9, 2021
Treatment considerations in node-positive prostate cancer
Author(s)Urology Times staff
Advertisement
Jason Zhu, MD, a medical oncologist at Levine Cancer Institute, part of Atrium Health, discusses factors he considers when choosing treatment for patients with lymph node–positive prostate cancer after prostatectomy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












